Ultragenyx agreed to sell a second rare pediatric Priority Review Voucher (PRV) for $203 million, following a prior voucher sale and after FDA approval of FAYUVI (rebisufligene etisparvovec-hopf). The transaction adds meaningful non-dilutive funding to support pipeline execution toward profitability. The company’s voucher proceeds increased its combined voucher monetization to $413 million in a short window, reinforcing how the PRV program can finance follow-on development after approvals. The buyer for the latest PRV sale was not disclosed, but the strategy signals continued reliance on regulatory incentives to sustain cash generation.